NCT03619187View on ClinicalTrials.gov

An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

November 2, 2018

Primary Completion Date

February 19, 2020

Study Completion Date

February 19, 2020

Conditions

Heart Transplantation, Elevated Resting Heart Rate

Interventions

DRUG

Ivabradine

Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg. The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.